Jiangsu Yahong Meditech Past Earnings Performance
Past criteria checks 0/6
Jiangsu Yahong Meditech's earnings have been declining at an average annual rate of -19.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 95455% per year.
Key information
-19.3%
Earnings growth rate
-14.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 95,455.0% |
| Return on equity | -18.3% |
| Net Margin | -1,104.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Jiangsu Yahong Meditech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 38 | -420 | 151 | 376 |
| 31 Dec 23 | 14 | -400 | 118 | 365 |
| 30 Sep 23 | 3 | -352 | 104 | 318 |
| 30 Jun 23 | 0 | -342 | 95 | 328 |
| 31 Mar 23 | 0 | -262 | 89 | 260 |
| 31 Dec 22 | 0 | -247 | 88 | 244 |
| 30 Sep 22 | 0 | -226 | 77 | 227 |
| 30 Jun 22 | 0 | -199 | 68 | 185 |
| 31 Mar 22 | 0 | -196 | 63 | 162 |
| 31 Dec 21 | 0 | -235 | 64 | 191 |
| 31 Dec 20 | 0 | -247 | 78 | 172 |
| 31 Dec 19 | 0 | -172 | 33 | 141 |
Quality Earnings: 688176 is currently unprofitable.
Growing Profit Margin: 688176 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688176 is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare 688176's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688176 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.6%).
Return on Equity
High ROE: 688176 has a negative Return on Equity (-18.3%), as it is currently unprofitable.